Zolpidem arousing effect in persistent vegetative state patients: autonomic, EEG and behavioral assessment

• Published in: Current pharmaceutical design Vol. 20; no. 26; p. 4185
• Main Authors: Machado, Calixto, Estévez, Mario, Rodríguez, Rafael, Pérez-Nellar, Jesús, Chinchilla, Mauricio, DeFina, Philip, Leisman, Gerry, Carrick, Frederick R, Melillo, Robert, Schiavi, Adam, Gutiérrez, Joel, Carballo, Maylén, Machado, Andrés, Olivares, Ana, Pérez-Cruz, Nuvia
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.01.2014
• Subjects: Adolescent; Adult; Autonomic Nervous System - drug effects; Autonomic Nervous System - physiopathology; Double-Blind Method; Electroencephalography; Female; Heart Rate - drug effects; Humans; Male; Middle Aged; Persistent Vegetative State - diagnosis; Persistent Vegetative State - drug therapy; Persistent Vegetative State - physiopathology; Pyridines - pharmacology; Pyridines - therapeutic use; Young Adult
• ISSN: 1873-4286

To study the Zolpidem arousing effect in persistent vegetative state (PVS) patients combining clinical evaluation, autonomic assessment by heart rate variability (HRV), and EEG records. We studied a group of 8 PVS patients and other 8 healthy control subjects, matched by age and gender. The patients and controls received drug or placebo in two experimental sessions, separated by 10-14 days. The first 30 minutes of the session were considered the basal record, and then Zolpidem was administered. All participants were evaluated clinically, by EEG, and by HRV during the basal record, and for 90 minutes after drug intake. We found in all patients, time-related arousing signs after Zolpidem intake: behavioral (yawns and hiccups), activation of EEG cortical activity, and a vagolytic chronotropic effect without a significant increment of the vasomotor sympathetic tone. We demonstrated time-related arousing signs after Zolpidem intake. We discussed possible mechanisms to explain these patho-physiological findings regarding EEG cortical activation and an autonomic vagolytic drug effect. As this autonomic imbalance might induce cardiocirculatory complications, which we didn't find in any of our patients, we suggest developing future trials under control of physiological indices by bedside monitoring. However, considering that this arousing Zolpidem effect might be certainly related to brain function improvement, it should be particularly considered for the development of new neuro-rehabilitation programs in PVS cases. According to the literature review, we claim that this is the first report about the vagolitic effect of Zolpidem in PVS cases.